Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs
- 1 February 1983
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 32 (7) , 795-800
- https://doi.org/10.1016/0024-3205(83)90315-6
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquineCanadian Journal of Physiology and Pharmacology, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Sparteine metabolism in Canadian CaucasiansClinical Pharmacology & Therapeutics, 1981
- Influence of the Genetically Controlled Deficiency in Debrisoquine Hydroxylation on Antipyrine Metabolite FormationPharmacology, 1981
- Deficient metabolism of debrisoquine and sparteineClinical Pharmacology & Therapeutics, 1980
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- Pharmacogenetics of tolbutamide metabolism in humansDiabetes, 1979
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- Apparent Michaelis constants for the metabolism of [ureyl-14C]tolbutamide by human liver microsomal preparationsBiochemical Pharmacology, 1972
- Spectral Studies on the Interaction of Imipramine and some of its Oxidized Metabolites with Rat Liver MicrosomesXenobiotica, 1971